Scynexis (SCYX) Cash & Equivalents (2013 - 2026)
Scynexis' (SCYX) quarterly Cash & Equivalents came in at $36.7 million in Q1 2026, down 31.84% YoY from $53.8 million in Q1 2025, and up 72.5% on a QoQ basis from $21.3 million in Q4 2025.
Scynexis (SCYX) Cash & Equivalents (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Cash & Equivalents data on file, last reported at $36.7 million in Q1 2026.
- Quarterly Cash & Equivalents fell 31.84% year-over-year to $36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.7 million (down 31.84% YoY) and the FY2025 annual result came in at $21.3 million, up 32.45% from the prior year.
- Cash & Equivalents advanced to $36.7 million in Q1 2026, from $21.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $118.7 million in Q2 2022 to a low of $11.0 million in Q2 2025.
- A 5-year average of $51.6 million and a median of $37.9 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents surged 53.31% — and 2025, when it slumped 86.83%.
- Tracing SCYX's Cash & Equivalents over 5 years: stood at $45.8 million in 2022, then decreased by 25.68% to $34.0 million in 2023, then tumbled by 52.86% to $16.1 million in 2024, then soared by 32.45% to $21.3 million in 2025, then surged by 72.5% to $36.7 million in 2026.
- The last three Cash & Equivalents figures came in at $36.7 million (Q1 2026), $21.3 million (Q4 2025), and $37.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - | 71.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.10 Mn |
| Mar 31, 2026 | 36.67 Mn |
| Dec 31, 2025 | 21.26 Mn |
| Sep 30, 2025 | 37.90 Mn |
| Jun 30, 2025 | 11.02 Mn |
| Mar 31, 2025 | 53.80 Mn |
| Dec 31, 2024 | 16.05 Mn |
| Sep 30, 2024 | 28.73 Mn |
| Jun 30, 2024 | 83.70 Mn |
| Mar 31, 2024 | 35.48 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Sep 30, 2023 | 105.20 Mn |
| Jun 30, 2023 | 57.91 Mn |
| Mar 31, 2023 | 26.91 Mn |
| Dec 31, 2022 | 45.81 Mn |
| Sep 30, 2022 | 68.62 Mn |
| Jun 30, 2022 | 118.70 Mn |
| Mar 31, 2022 | 95.21 Mn |
| Dec 31, 2021 | 104.48 Mn |
| Sep 30, 2021 | 100.11 Mn |